<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01925859</url>
  </required_header>
  <id_info>
    <org_study_id>IED-PK01-2013</org_study_id>
    <nct_id>NCT01925859</nct_id>
  </id_info>
  <brief_title>EryDex Pharmacokinetics in Healthy Volunteers</brief_title>
  <acronym>EryDex</acronym>
  <official_title>Pharmacokinetics Study to Measure Plasma Concentrations of Dexamethasone Following EryDex (Dexamethasone Sodium Phosphate Encapsulated in Autologous Erythrocytes) Infusion in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erydel</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Erydel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the pharmacokinetic properties of two different doses of EryDex (dexamethasone
      sodium phosphate encapsulated in erythrocytes) given as a single infusion in healthy
      volunteers, based on plasma concentrations of dexamethasone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic comparison of two different doses of EryDex in two independent groups</measure>
    <time_frame>42 days after infusion</time_frame>
    <description>• To compare the pharmacokinetic (PK) properties of 2 different doses of EryDex (dexamethasone sodium phosphate encapsulated in erythrocytes) given as a single infusion in healthy volunteers, based on plasma concentrations of dexamethasone.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of safety and tolerability of a single infusion of EryDex administered in two different doses in healthy volunteers</measure>
    <time_frame>84 days after infusion</time_frame>
    <description>• To evaluate the safety and tolerability of a single infusion of EryDex, administered at 2 different doses in healthy volunteers, based on the following: Treatment-Emergent Adverse Events (TEAEs), Serious AEs (SAEs), laboratory parameters, vital signs, ECGs and physical examination findings.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>EryDex System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>erythrocytes encapsulated with dexamethasone sodium phosphate (EryDex System)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EryDex (dexamethasone sodium phosphate encapsulated erythrocytes)</intervention_name>
    <description>erythrocytes encapsulated with dexamethasone sodium phosphate (EryDex System)-corresponding to either 50 mg OR 125mg of experimental study drug</description>
    <arm_group_label>EryDex System</arm_group_label>
    <other_name>EryDex System (dexamethasone sodium phosphate encapsulated erythrocytes)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ages 18-55 years, inclusive.

          2. If female, the subject is not pregnant or lactating, and has negative serum pregnancy
             tests at Screening and Baseline (check-in).

          3. If female of childbearing potential*, the subject agrees not to donate ova and to use
             one of the following methods of contraception from the time of signing the informed
             consent until 2 months after infusion.

               1. Cap or diaphragm with spermicidal cream or jelly + male condom and spermicide.

               2. Hormonal contraceptives (oral, implant, injection or patch) + male condom and
                  spermicide.

               3. Intrauterine devices + male condom or spermicide.

               4. Vaginal ring + male condom and spermicide.

                    -  Non-childbearing potential is defined as surgical sterilization
                       (hysterectomy, bilateral oophorectomy, or bilateral tubal ligation),
                       hysterectomy at least 3 months before the start of the study, or
                       postmenopausal (defined as continuous amenorrhea for at least 2 years).

          4. If male, the subject agrees to not donate sperm and to use barrier contraception
             (e.g., condom with spermicidal cream or jelly) from the time of signing the informed
             consent until 2 months after infusion.

          5. Physically and mentally healthy, as confirmed by medical history, physical
             examination, vital signs, clinical laboratory tests, and ECG.

          6. The subject has a body weight of at least 45 kg and a body mass index of ≤ 30.

          7. Written informed consent to participate was obtained from the subject.

          8. Ability to understand the aims of the trial and comply with the study procedures.

        Exclusion Criteria:

          -  General

               1. Females that are of childbearing potential, pregnant, or are breast-feeding.
                  Women of childbearing potential using two forms of birth control (e.g. barrier
                  and hormonal) will be eligible.

               2. Loss/removal of 500 mL or more of blood within the past 4 weeks.

               3. A disability that may prevent the subject from completing all study requirements.

               4. Noncompliance with the study requirements. Medical History

               5. Current or previous neoplastic disease.

               6. History of any impairment of the immunological system.

               7. History of drug or alcohol abuse (within past 5 years).

               8. A current diagnosis of severe or unstable cardiovascular disease;

               9. Any history or current evidence of a cardiac illness as determined by the
                  investigator;

              10. History or current diagnosis of a psychiatric illness (DSM-IV-TR Axis I
                  diagnosis) or neurodegenerative disorder.

              11. Smoker; currently or at any time in the last 6 months.

              12. Hemoglobinopathy or G6PD deficiency.

              13. History of recurrent or chronic infections, including Staphylococcus or
                  methicillin-resistant Staphylococcus aureus (MRSA).

              14. History of positive tuberculosis skin test (PPD test). Current Medical Status

              15. Have any other significant disease or condition that in the Investigator's
                  opinion would put the subject at risk for participating in the trial.

              16. Vital signs outside the following ranges:

                    1. Systolic blood pressure &lt;90 or &gt;140 mmHg

                    2. Diastolic blood pressure &lt;50 or &gt;90 mmHg

                    3. Pulse &lt;50 or &gt;90 bpm. Patients with pulse rates &lt;50 that are otherwise
                       healthy will be eligible for the trial if approved by the Sponsor.

              17. Any clinically significant ECG abnormality, including a disorder of rate, rhythm,
                  or conduction, or other morphological changes.

              18. Any clinically significant abnormality on standard laboratory examinations
                  (hematology, biochemistry, urinalysis), as determined by the Investigator, in
                  consultation with the Sponsor.

              19. History of hepatitis B and/or C, and/or positive serology results, which indicate
                  the presence of hepatitis B and/or C (Hepatitis B surface antigen and/or antibody
                  to Hepatitis C).

              20. Positive results from the HIV serology.

              21. Positive results of the drug and alcohol tests at screening and/or check-in at
                  the unit. Alcohol intake should be limited to 2 drinks per day during the 2 weeks
                  prior to dosing; alcohol consumption will be prohibited from the time o

              22. Clinically significant abnormal serum cortisol levels (below normal range or
                  &gt;1.5x ULN) at screening.

                  Prior/Concomitant Medication

              23. Any previous steroid consumption within 4 weeks before Baseline.

              24. Chronic condition or prior allergic reaction representing a contraindication to
                  the use of steroid drugs.

              25. Have participated in any other trial with an investigational drug and received a
                  dose within 30 days or 10 half-lives (whichever is greater) from the start of the
                  Screening Period.

              26. Requirement for any prescription or over-the-counter (OTC) medication, other than
                  hormonal birth control or occasional use of acetaminophen, that cannot be
                  discontinued during screening, at least one week before Baseline, and throughout
                  the 42-day study period.

                  f admittance on Day -1 through to the final safety evaluations on Day 42.

              27. A drug or treatment known to cause major organ system toxicity during the past
                  year.

              28. Caffeine-containing products in excess of the equivalent of 2 cups of coffee per
                  day during the 2 weeks prior to dosing and through to the final safety
                  evaluations on Day 42.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed Al-Ibrahim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SNBL Pharmacology Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SNBL Clinical Pharmacology Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 14, 2013</study_first_submitted>
  <study_first_submitted_qc>August 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2013</study_first_posted>
  <last_update_submitted>May 29, 2015</last_update_submitted>
  <last_update_submitted_qc>May 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetic analysis</keyword>
  <keyword>EryDex</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

